A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Conditions: Glioma; Glioblastoma Multiforme Intervention: Drug: APG-157 Sponsor: Aveta Biomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Conditions: Glioma; Glioblastoma Multiforme Intervention: Drug: APG-157 Sponsor: Aveta Biomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Conditions: Glioma; Glioblastoma Multiforme Intervention: Drug: APG-157 Sponsor: Aveta Biomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Conditions: Glioma; Glioblastoma Multiforme Intervention: Drug: APG-157 Sponsor: Aveta Biomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Conditions: Glioma; Glioblastoma Multiforme Intervention: Drug: APG-157 Sponsor: Aveta Biomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Conditions: Glioma; Glioblastoma Multiforme Intervention: Drug: APG-157 Sponsor: Aveta Biomics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Condition: Colo-rectal Cancer Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil; Biological: Bevacizumab; Drug: Irinotecan; Biological: Cetuximab; Procedure: Metastasectomy; Procedure: Biospecimen collection Sponsor: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Condition: Epithelial Ovarian Cancer Intervention: Drug: Envafolimab Sponsor: Hebei Medical University Fourth Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2023 Category: Research Source Type: clinical trials
